Q32 Bio (QTTB) Shares Outstanding (Diluted Average) (2021 - 2026)
Q32 Bio (QTTB) recorded quarterly Shares Outstanding (Diluted Average) of $14.1 million in Q1 2026, up 14.46% quarter-over-quarter from $12.3 million in Q4 2025, and up 15.56% on a YoY basis from $12.2 million in Q1 2025.
Q32 Bio (QTTB) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Q32 Bio's Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $14.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 15.56% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (up 15.56% YoY), while the FY2025 annual figure was $12.3 million, up 27.51% from the prior year.
- Shares Outstanding (Diluted Average) was $14.1 million for Q1 2026 at Q32 Bio, up from $12.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $57.9 million in Q1 2022 to a low of $344623.0 in Q1 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $19.3 million across 5 years, with a median of $12.2 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) sank 99.4% in 2023, then soared 3338.63% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $57.4 million in 2022, then tumbled by 99.39% to $349060.0 in 2023, then surged by 2666.77% to $9.7 million in 2024, then increased by 27.51% to $12.3 million in 2025, then grew by 14.46% to $14.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $14.1 million (Q1 2026), $12.3 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | 14.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.10 Mn |
| Dec 31, 2025 | 12.31 Mn |
| Sep 30, 2025 | 12.21 Mn |
| Jun 30, 2025 | 12.20 Mn |
| Mar 31, 2025 | 12.20 Mn |
| Dec 31, 2024 | 9.66 Mn |
| Sep 30, 2024 | 8.81 Mn |
| Jun 30, 2024 | 11.96 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Dec 31, 2023 | 349,060.00 |
| Sep 30, 2023 | 346,288.00 |
| Jun 30, 2023 | 347,936.00 |
| Mar 31, 2023 | 344,623.00 |
| Dec 31, 2022 | 57.40 Mn |
| Sep 30, 2022 | 57.45 Mn |
| Jun 30, 2022 | 57.39 Mn |
| Mar 31, 2022 | 57.88 Mn |
| Dec 31, 2021 | 55.28 Mn |
| Sep 30, 2021 | 57.11 Mn |
| Jun 30, 2021 | 53.43 Mn |